Find an abstract and a link to most of the publications produced by Nordic Bioscience
Type I IFNs are implicated in the pathophysiology of systemic sclerosis (SSc). Recently, a Phase I open-label trial was conducted with an anti-IFNAR1 receptor antibody (anifrolumab) in adult SSc patients. In this study, we aim to assess the downstream effects of anifrolumab and elucidate the role of...
October 1, 2015
Journal:
J Invest Dermatol
Author:
Guo X, Higgs BW, Bay-Jensen AC, Karsdal MA, Yao Y, Roskos LK, White WI
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.